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MicroRNAs and heterogeneous ribonucleoproteins
(hnRNPs) are posttranscriptional gene regulators
that bind mRNA in a sequence-specific manner.
Here, we report that loss of miR-328 occurs in blast
crisis chronic myelogenous leukemia (CML-BC) in
a BCR/ABL dose- and kinase-dependent manner
through the MAPK-hnRNP E2 pathway. Restoration
of miR-328 expression rescues differentiation and
impairs survival of leukemic blasts by simultaneously
interacting with the translational regulator poly(rC)-
binding protein hnRNP E2 and with the mRNA
encoding the survival factor PIM1, respectively. The
interaction with hnRNP E2 is independent of the
microRNA’s seed sequence and it leads to release
of CEBPA mRNA from hnRNP E2-mediated transla-
tional inhibition. Altogether, these data reveal the
dual ability of a microRNA to control cell fate both
through base pairing with mRNA targets and through
a decoy activity that interferes with the function of
regulatory proteins.
INTRODUCTION
Dysfunctional posttranscriptional gene regulation by sequence-
specific RNA-binding proteins (RBPs) plays a critical role in the652 Cell 140, 652–665, March 5, 2010 ª2010 Elsevier Inc.pathogenesis and evolution of human diseases (Carpenter
et al., 2006; Glisovic et al., 2008; Keene, 2007), including the
blastic phase of chronic myelogenous leukemia (Melo and
Barnes, 2007; Perrotti and Neviani, 2007). In this disease stage,
increased activity of the BCR/ABL oncoprotein alters process-
ing, export, and/or translation of mRNAs encoding tumor
suppressors, oncoproteins, and critical regulators of differentia-
tion by aberrantly modulating the expression and function of
RBPs with sequence-specific mRNA-binding activity (Eiring
et al., 2008; Perrotti and Neviani, 2007). Differentiation arrest in
myeloid blast crisis chronic myelogenous leukemia (CML-BC)
depends on the BCR/ABL-MAPK-induced activity of hnRNP
E2 (Chang et al., 2007; Perrotti et al., 2002), a poly(rC)-binding
protein that controls translation of specific mRNAs (Ostareck-
Lederer and Ostareck, 2004). In CML-BC, but not chronic phase
(CML-CP) CD34+ bone marrow (BM) progenitors, hnRNP E2 is
highly expressed and, upon interaction with the C-rich element
in the 50 untranslated region (UTR) ofCEBPAmRNA, suppresses
translation (Chang et al., 2007; Perrotti et al., 2002) of this master
regulator of myeloid differentiation (Tenen, 2003).
hnRNP E2 RNA-binding activity does not require posttransla-
tional modifications, and its expression is transiently induced by
cytokines (e.g., IL-3) in myeloid precursors (Chang et al., 2007).
Nonetheless, the early stages of myelopoiesis are characterized
by cytokine-dependent proliferation and C/EBPa-mediated
differentiation, suggesting that the hnRNP E2:CEBPA interaction
might be prevented by a hnRNP E2-interacting protein or RNA,
or by another RBP interacting with the CEBPA 50UTR. Because
small noncoding RNAs are regulators of critical cell functions
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Figure 1. miR-328 Is Downregulated in CML-BC
(A) hnRNP E2 consensus binding sites (red) in the precursor and mature (gray box) miR-328 and in the CEBPA uORF/spacer region.
(B) Left:Northern blot andRT-PCR showmiR-328 levels andwestern blot showsBCR/ABL levels in 32Dcl3 and untreated or imatinib-treated 32D-BCR/ABL cells;
right: northern blot and RT-PCR show miR-328 levels in vector- and BCR/ABL-infected lineage-negative (Lin) mouse BM cells.
(C) qRT-PCR shows miR-328 levels in untreated (n = 3) and imatinib-treated (n = 3) Lin BM cells from leukemic SCLtTA-BCR/ABL mice (left) and in CD34+ BM
progenitors from CML-CP (n = 6) and CML-BC (n = 6) patients (right). snRNA U6 and GRB2 levels were used as loading controls (mean ± standard error of the
mean [SEM]).including normal and leukemic hematopoiesis (Chen et al., 2004;
Garzon et al., 2006), we hypothesized that differentiation arrest
of myeloid CML-BC blasts results from impaired expression of
a microRNA (miRNA) that, in addition to exerting its gene
silencing activity through canonical binding to mRNA regulatory
regions (Bartel, 2009; Friedman et al., 2009), also strongly com-
petes with CEBPA mRNA for binding to hnRNP E2. Here, we
report the existence of miRNA-dependent posttranslational
control of biological processes through both base pairing with
complementary mRNAs and sequence-dependent interference
with the mRNA-regulatory function of RNA-binding proteins
(decoy activity).RESULTS
BCR/ABL-Dependent Downregulation of miR-328
Expression
Comparative miRNA arrays revealed that a discrete number of
miRNAs were more than 3-fold modulated in a BCR/ABL dose-
and kinase-dependent manner in cell line models and patient-
derived myeloid CML-BCCD34+ versus CML-CPCD34+ BM pro-
genitors (not shown). Among the miRNAs downregulated in
CML-BCCD34+, we focused on miR-328 because its mature
form harbors a C-rich element that resembles the negative regu-
latory hnRNP E2-binding site contained in the CEBPA intercis-
tronic mRNA region (Figure 1A).
Northern blot and qRT-PCR analyses confirmed that miR-328
downregulation is markedly induced by BCR/ABL expression
in 32Dcl3 myeloid precursors (32D-BCR/ABL) and primary
lineage-negative (Lin) mouse BM cells (Figure 1B). Reduction
of miR-328 expression depends on BCR/ABL kinase activity
as imatinib treatment (2 mM; 24 hr) significantly increased
miR-328 expression in 32D-BCR/ABL andK562 cells (Figure 1B),
as well as in Lin BM cells from leukemic SCLtTA-BCR/ABL
mice (n = 3/group) (Figure 1C). As expected, imatinib did not
rescue miR-328 levels in imatinib-resistant BCR/ABL(T315I)
cells (not shown). Finally, miR-328 expression was also signifi-cantly reduced in myeloid CML-BCCD34+ (n = 6) compared to
CML-CPCD34+ (n = 6) BM patient cells (Figure 1C), suggesting
its possible involvement in blastic transformation.miR-328 Competes with CEBPA mRNA for Binding
to hnRNP E2
To determine whether the C-rich element present in mature
miR-328 is a bona fide hnRNP E2-binding site, RNA electropho-
retic mobility shift assays (REMSA), UV crosslinking, and RNA
immunoprecipitation (RIP) assays were performed using malt-
ose-binding protein (MBP)-tagged hnRNP E2 (MBP-hnRNP
E2), 32D-BCR/ABL cytoplasmic cell lysates expressing high
levels of hnRNP E2 (Perrotti et al., 2002), and/or lysates of
32Dcl3 and 32D-BCR/ABL cells expressing a Flag-tagged
hnRNP E2. REMSA (Figure 2A and Figure S1A available online)
and UV crosslinking (Figure 2B) revealed that a 32P-labeled
miR-328 oligoribonucleotide efficiently formed a complex with
recombinant, endogenous, and ectopic hnRNP E2 proteins but
not with MBP alone or lysates of 32Dcl3 cells. Accordingly, the
mobility of hnRNP E2:miR-328 complexes was identical to that
formed using the uORF/spacer region of CEBPAmRNA (CEBPA
uORF) oligoribonucleotide (Figures 2A and 2B), and miR-328
binding to hnRNP E2was four times stronger than that ofCEBPA
uORF (Figure 2A). By contrast, the BCR/ABL-regulatedmiR-330,
which is not C-rich, neither interacted with hnRNP E2 nor
disturbed hnRNP E2:miR-328 complex formation (Figures 2A
and 2B). miR-328 and CEBPA uORF binding to endogenous
hnRNP E2 was also impaired by imatinib (Figure 2A) that, report-
edly, inhibits hnRNP E2 expression in BCR/ABL+ cells (Chang
et al., 2007).
To determine whether hnRNP E2:miR-328 interaction requires
integrity of the miRNA seed sequence (Figure 2B, underlined
nucleotides) that, as known, is essential for canonical miRNA:
mRNA target interaction, UVcrosslinking assayswere performed
using 32D-BCR/ABL and 32D-Flag-E2 lysates, as well as a
miR-328oligoribonucleotideharboringamutatedseedsequence
that retains the wild-type C-rich character (miR-328-Mut)Cell 140, 652–665, March 5, 2010 ª2010 Elsevier Inc. 653
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Figure 2. miR-328 Competes with CEBPA mRNA for Binding to hnRNP E2
(A) REMSA shows binding of miR-328, CEBPA uORF, and miR-330 RNA probes to MBP-tagged hnRNP E2 (lanes 2, 4, 6, 7–12), MBP (lanes 1, 3, 5), and cyto-
plasmic lysates of 32Dcl3 (lanes 14, 19) and untreated or imatinib-treated 32D-BCR/ABL cells (lanes 13, 15–18, 20–22). Cold competitor RNAs were used as
indicated (lanes 8–9, 11–12, 17–18, 22).
(B) Top: UV crosslinking shows binding of miR-328 (lanes 1–3 and 10),CEBPA uORF (lanes 4–6), the seed sequence-mutatedmiR-328 (miR-328-Mut) (lanes 7–9),
and miR-330 (lane 11) to hnRNP E2 in 32Dcl3, 32D-BCR/ABL, and 32D-Flag-E2 cell lysates (lanes 1–6). Bottom: Western Blots show levels of hnRNP E2 and
GRB2 in the lysates used in UV crosslinking. Sequence of thewild-type and seed sequence-mutatedmiR-328with substituted nucleotides indicated by asterisks.
(C) RNA Immunoprecipitation (RIP) assay for miR-328 performed on anti-hnRNP E2 immunoprecipitates (IPs) from lysates of untreated (lane 3), imatinib-treated
(lane 5), and pSR-miR-328-transduced (lane 7) 32D-BCR/ABL (6.15 clone) cells. RIP with a nonrelated IgG served as controls (lane 8). IN: input RNA; MWM:
molecular weight marker (lane 1); NTC: nontemplate control; -RT: no reverse transcribed PCR reaction. RIP was also observed with ectopically expressed
Flag-hnRNP E2 proteins (see Figure S1).
(D) Left: RIP assays forCEBPAmRNA (top) andmiR-328 (bottom) performed on anti-hnRNPE2 (lanes 5 and 9) and nonrelated IgG (lanes 3 and 7) IPs fromparental
(lanes 2–5) and miR-328-expressing (lanes 6–9) 32D-BCR/ABL cells. IN: RNA input; MWM: molecular weight marker (lane 1); NTC: nontemplate PCR control.
hnRNP E2 RIP assays for a nonrelated mRNA (i.e., SET) are reported in Figure S1. Inset top right: Northern blot shows levels of ectopic miR-328 in vector- (lanes
1 and 3) andmiR-328-transduced (lanes 2 and 4) 32Dcl3 and 32D-BCR/ABL cells. snRNAU6was analyzed for normalization. Right: Densitometric analyses of the
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Figure 3. hnRNP E2:miR-328 Interaction Does Not Associate with
the RISC Loading Complex
Western blots show levels of Dicer, TRBP2, Ago2, and/or hnRNP E2 in cyto-
plasmic lysates (input; lanes 1 and 4), in anti-hnRNP E2 (A) and anti-Dicer (B)
IPs (lane 3), in IPs with an isotype-matched IgG (lane 2), and in hnRNP E2-
andDicer- immunodepleted (ID) lysates (lane5)of 32D-BCR/ABL-miR-328cells.
(C)RIPassay formiR-328onanti-Dicer (lane4), anti-hnRNPE2 (lane5), andanti-
Ago2 (lane 7) IPs from 32D-BCR/ABL-miR-328 cell lysates. Note that the anti-
hnRNP E2 RIP for miR-328 was performed on Dicer-immunodepleted lysates.
RIP with a nonrelated IgG served as a negative control.(Figure 2B). As shown (Figure 2B), miR-328-Mut binds both
endogenous and ectopic hnRNP E2 at higher affinity than wild-
type miR-328, suggesting that the C-rich character rather than
the seed sequence is important for hnRNP E2 interaction.
Furthermore, the hnRNP E2:miR-328 interaction was also
demonstrated in living cells by RIP assay. In fact, endogenous
miR-328 was found associated with endogenous hnRNP E2 in
anti-hnRNP E2 but not anti-IgG immunoprecipitates (IP) from
imatinib-treated 32D-BCR/ABL cells (Figure 2C). As expected,
no binding was detected in untreated IL-3-cultured 32D-BCR/
ABL cells (Figure 2C). Ectopic expression of miR-328 at physio-
logical levels (Figure 2D and Figure S1B) also resulted in complex
formation with both ectopic (Figure S1C) and endogenous (Fig-
ures 2C and 2D and Figure S1D) hnRNP E2. Note that Flag-
hnRNP E2 did not significantly alter total hnRNP E2 levels
(Figure S1A) and that miR-328 binding to hnRNP E2 impaired
(80% inhibition) hnRNP E2:CEBPA association (Figures 2D
and 2E and Figure S1D). Furthermore, qRT-PCR analyses per-
formed on anti-hnRNP E2 RIPs revealed that 4.26% ± 0.56% (n
= 3) of the total miR-328 was associated to hnRNP E2 (not
shown). As expected, hnRNP E2 did not interact with either a
BCR/ABL-induced mRNA (i.e., SET) or the endogenous C-rich
miR-223 (Figure S1D). Accordingly, ectopicmiR-181bdid neither
interact with hnRNP E2 nor significantly alter levels of the hnRNP
E2:CEBPA complex (Figure 2E). Thus, miR-328 specifically
competes with CEBPAmRNA for binding to hnRNP E2.
hnRNP E2:miR-328 Interaction Does Not Associate
with the RISC Loading Complex
To assess whether the hnRNP E2:miR-328 interaction occurs in
the presence of major components of the RISC loading complex
(Chendrimada et al., 2005), we evaluated whether hnRNP E2 is
in complex with Dicer, Ago2, or TRBP2. Anti-hnRNP E2 and
anti-Dicer (Figures 3A and 3B) coimmunoprecipitation (coIP)
experiments clearly show that hnRNP E2 did not interact with
Dicer, TRBP2, or Ago2. Likewise, hnRNP E2 or Dicer immunode-
pletion did not alter levels of RISC components (Ago2 and
TRBP2) or hnRNP E2, respectively (Figures 3A and 3B). As ex-
pected, TRBP2 was readily detectable in anti-Dicer IPs (Fig-
ure 3B). Thus, hnRNP E2:miR-328 interaction does not appear
to require association with RISC loading components. However,
RIP assays revealed miR-328 in complex with both Dicer and
Ago2 (Figure 3C), suggesting that miR-328 also functions as
a silencer of mRNA targets in a canonical RISC-dependent
manner and that, most likely, its binding to hnRNP E2 is not
mutually exclusive. Indeed, the presence of readily detectable
hnRNP E2:miR-328 complex in RIP assays on Dicer-immunode-
pleted lysates (Figure 3C, lane 5) suggests that miR-328 might
interact with hnRNP E2 in a RISC-independent manner.levels of CEBPAmRNA andmiR-328 associated to hnRNP E2 evaluated by RIP a
bars) 32D-BCR/ABL cells (mean ± SEM).
(E) Left: RIPassays forCEBPAmRNA (top) on anti-hnRNPE2 IPs fromvector (pSup
cells; RIP assays formiR-181b (middle) andmiR-328 (bottom) on anti-hnRNPE2 IP
UV crosslinking with miR-328, miR-181b, and miR-330 32P-labeled oligoribonucle
(lanes 2, 4, and 6) cells. Binding of hnRNP E2 to miR-328 is shown in lane 2. Inset
(black), vector- (gray), and pSUP-miR-181b-transduced (white) 32D-BCR/ABL c
associated to hnRNP E2 (n = 3), expressed as percentage of the input RNA (IN),
SEM). Controls for endogenous and ectopic hnRNP E2 protein and miR-328 exprmiR-328 Rescues C/EBPa-Driven Granulocytic
Differentiation of CML-BCCD34+ Progenitors
As loss of miR-328 may influence the phenotype of CML-BC
myeloid blasts, we evaluated proliferation, clonogenic potential,ssays (n = 4) performed with parental (light bars) and miR-328-expressing (dark
er)- (lane5),miR-328- (lane7), andmiR-181b-transduced (lane9) 32D-BCR/ABL
s frommiR-181b-expressing 32D-BCR/ABL cells (lanes 8 and 9). Inset top right:
otides and cytoplasmic lysates of 32Dcl3 (lanes 1, 3, and 5) and 32D-BCR/ABL
bottom left: Graph shows qRT-PCR analysis of miR-181b expression in 32Dcl3
ells (mean ± SEM). Right: Densitometric analysis of the RIP’ed CEBPA mRNA
in vector-, miR-328-, and miR-181b-transduced 32D-BCR/ABL cells (mean ±
ession levels and the specificity of the RIP protocol are shown in Figure S1.
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Figure 4. miR-328 Rescues Granulocytic Differentiation through Restoration of C/EBPa Expression
(A) miR-328 levels in (left) 32Dcl3 cells undergoing G-CSF-induced differentiation; (middle) Lin/Sca+/Kit+ HSC, CMP/GMP/MEP committed progenitors and
mature neutrophil BM subpopulations from wild-type C57BL/6 mice (mean ± SEM); and (right) CD34+ human BM cells undifferentiated (white) and induced to
differentiate for the indicated time toward the erythroid (light gray), megakaryocytic (dark gray), granulocytic (red), or monocytic (black) lineages (mean ± SEM).
(B) Wright-Giemsa-stained cytospins of G-CSF-treated (0–7 days) pSuper-, miR-328-, miR-328-Mut-, miR-223-, and/or miR-181b-infected 32Dcl3 and/or 32D-
BCR/ABLcells (mean±SEM).LevelsofmiR-223 inBCR/ABL+cell linesandprimary cells andeffectof ectopicmiR-223oncell proliferationare reported in FigureS2.
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and G-CSF-driven differentiation in miR-328-transduced GFP+
BCR/ABL+ cell lines, BCR/ABL+ Lin mouse BM, and/or CML-
BCCD34+ cells. As controls, we assessed the effects of ectopic
miR-328-Mut, miR-181b, and the myeloid differentiation-related
(Chen et al., 2004) miR-223 in BCR/ABL+ cells. Of note, ectopic
miR-328 or miR-223 levels in BCR/ABL+ cells were similar to
those in nontransformed cells (Figure 2D and Figure S2A), thus
excluding off-target effects due to overexpression.
Although endogenous miR-328 (Figure 1) and, to a lower
extent, miR-223 (Figure S2B) were downregulated in 32D-
BCR/ABL and K562 cells, their ectopic expression did not
have a significant effect on IL-3-dependent and/or -independent
growth (Figure S2B). Likewise, ectopic miR-328 did not accel-
erate the kinetics of 32Dcl3 neutrophil maturation (Figure 4B),
consistent with the barely detectable levels of hnRNP E2 in
32Dcl3 cells (Perrotti et al., 2002) and the increased expression
of endogenous miR-328 in 32Dcl3, human CD34+ (n = 2) and
mouse Lin/Sca+/Kit+ (n = 3) BM (NBM) progenitors undergoing
granulocytic differentiation (Figure 4A). Conversely, miR-328
levels were not significantly different in normal CD34+ BM cells
before and after differentiation toward other hematopoietic line-
ages (Figure 4A). As expected (Fazi et al., 2005), miR-223
enhanced 32Dcl3 differentiation (not shown).
In agreement with the potential role of miR-328 as an antago-
nist of hnRNP E2 differentiation inhibitory activity, forced expres-
sionofmiR-328 at physiological levels (Figure 2DandFigureS2A)
efficiently rescued granulocytic differentiation of newly estab-
lished (15 days after BCR/ABL infection) 32D-BCR/ABL cells
(Figure 4B). In fact, the majority (82.1% ± 3.9%) of miR-328-
expressing 32D-BCR/ABL cells were postmitotic metamyelo-
cytes, bands, and segmented neutrophils after 7 days of G-CSF-
supplemented culture (Figure 4B). As expected, G-CSF-treated
vector- and miR-181b-transduced BCR/ABL+ cells remained
blasts (5.1% ± 0.5% and 11.0% ± 3.2% postmitotic cells)
(Figure 4B). By contrast, miR-328-Mut expression efficiently
induced 32D-BCR/ABL differentiation (88.6% ± 3.1% postmi-
totic cells) (Figure 4B).
Although terminal differentiation was also a characteristic
of miR-223-overexpressing 32D-BCR/ABL cells, only ectopic
miR-328 but not miR-223 expression (Figure S2C) restored
G-CSF-driven maturation of GFP+ CD34+ BM progenitors from
myeloid CML-BC patients (n = 6) (Figure 4C). In fact, both miR-
328- and miR-328-Mut-expressing CML-BCCD34+ BM cultures
became bands and segmented neutrophils (88.8% ± 2.4% and
85.2% ± 4.2% postmitotic cells) after 10 days in rhG-CSF
(25 ng/ml). By contrast, morphology of miR-223-expressing
CML-BCCD34+ (n = 6) progenitors remained similar to untrans-
duced cells (n = 6), appearing arrested at the myeloblast stage
after 7–10 days in G-CSF-containing medium (16.9% ± 1.7%(C) Wright-Giemsa-stained cytospins of primary G-CSF-treated (0–10 days) unin
progenitors (mean ± SEM). For levels of ectopic miR-328 and miR-223 expression
(D)Myeloperoxidase (MPO) immunostaining of G-CSF-treated uninfected andmiR
of three independent experiments (mean ± SEM).
(E) Western blot shows C/EBPa, hnRNP E2, and GRB2 levels in G-CSF-treated 32
infected 32D-BCR/ABL and CML-BCCD34+ BM cells (right).
(F) qRT- PCR shows levels of CEBPA in empty vector-, miR-223-, or miR-328-infe
empty vector-, miR-223-, or miR-328-transduced 32D-BCR/ABL cells (mean ± SEpostmitotic cells) (Figure 4C) with unchanged levels of the gran-
ulocyte/macrophage markers CD11b or CD14 (not shown).
Consistent with the essential role of C/EBPa in neutrophil
maturation of BCR/ABL+ blasts (Ferrari-Amorotti et al., 2006;
Perrotti et al., 2002; Wagner et al., 2006), C/EBPa expression
was readily detectable in miR-223- and miR-328-transduced
32D-BCR/ABL myeloid precursors, and in miR-328- but not
miR-223-expressing CML-BCCD34+ BM progenitors and miR-
181b-expressing 32D-BCR/ABL cells (Figure 4E). This was
dependent neither on hnRNP E2 downregulation (Figure 4E)
nor on increased CEBPA mRNA levels (Figure 4F and Fig-
ure S2C). In agreement with its ability to bind hnRNP E2, miR-
328-Mut also restored C/EBPa expression (Figure 4E), indicating
that the differentiation-promoting effects of miR-328 do not
result from the seed sequence-dependent silencing of miR-328
mRNA targets. Furthermore, myeloperoxidase (MPO), a marker
of granulocyte/macrophage commitment and a direct transcrip-
tional target of C/EBPa (Rosmarin et al., 1989;Wang et al., 2001),
was also significantly increased in G-CSF-cultured miR-328-
(18.7% ± 0.2% [uninfected] versus 53.3% ± 7.3% [miR-328];
p < 0.004) but not miR-223- (18.7% ± 0.2% [uninfected] versus
22.2% ± 3.6% [miR-223]; p = 0.28) expressing CML-BCCD34+
cells (n = 3) (Figure 4D). Finally, the dissimilar response of miR-
223-transduced 32D-BCR/ABL versus CML-BCCD34+ progeni-
tors to G-CSF might depend on differences in the mechanism(s)
controlling expression of NFI-A (Figure S2D), a miR-223-nega-
tive regulator (Fazi et al., 2005).
miR-328 Restores CEBPA mRNA Translation
Both In Vitro and In Vivo
As hnRNP E2:miR-328 binding in vitro is more efficient than that
ofCEBPA uORF (Figure 2), andmiR-328 expression antagonizes
hnRNP E2:CEBPA interaction (Figures 2D and 2E) most likely by
competing for binding to hnRNP E2, it is plausible that miR-328
releases CEBPA from the translation inhibitory effects of hnRNP
E2. Thus, we assessed the effect of miR-328 on CEBPA transla-
tion in rabbit reticulocyte lysate and in an in vivo mouse model of
myeloid CML-BC. In the latter, BCR/ABL+ cell differentiation is
driven solely by ectopic C/EBPa expression, which is under
the control of its uORF/spacer mRNA element (Chang et al.,
2007). As reported (Perrotti et al., 2002), translation of CEBPA
mRNA was markedly impaired (80% inhibition) in in vitro trans-
lation reactions programmedwith aCEBPA construct containing
the uORF/spacer intercistronic region (pcDNA3-WT-uORF-C/
EBPa) and the recombinant fusion protein MBP-hnRNP E2
(Figure 5A) but not when performed in the absence of exogenous
hnRNP E2 (Figure 5A). Addition of 1000-fold excess of mature
miR-328 but not miR-330 resulted in an almost 100% increase
of newly synthesized 35S-C/EBPa protein (CEBPA+hnRNP E2fected and miR-328-, miR-328-Mut-, and miR-223-infected CML-BCCD34+ BM
in primary CML-BC cells, see Figure S2.
-328- andmiR-223-transducedCML-BCCD34+ BMcells. Data are representative
Dcl3 and empty vector-, miR-328-, miR-223-, miR-328-Mut-, and/or miR-181b-
cted CML-BC cells (mean ± SEM). qRT- PCR showing CEBPAmRNA levels in
M) is reported in Figure S2.
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versusCEBPA+hnRNP E2+miR-328; p < 0.005) (Figure 5A). Note
that addition of miR-328 in the absence of MBP-hnRNP E2 did
not significantly affect CEBPA mRNA translation (Figure 5A).
Moreover, the large amount of MBP-hnRNP E2 (Figure 5A) might
justify the incomplete rescue of CEBPA translation.
To assess whether forced miR-328 expression rescues
neutrophilic maturation of differentiation-arrested BCR/ABL+
blasts through restoration of CEBPA mRNA translation, we
used the aberrant 32D-BCR/ABL long-term cultured 6.15 cell
clone that exhibits extremely high levels of BCR/ABL and hnRNP
E2 but is unable to undergo G-CSF-driven differentiation due to
transcriptional suppression of CEBPa expression (Figure 5C).
Indeed, 6.15 cells completely rely on translation of ectopic
CEBPA mRNA for differentiation. Thus, parental and 6.15 cells
expressing a GFP-WT-uORF/spacer-C/EBPa (6.15-WT-uORF),
which contains the hnRNP E2 translation inhibitory element,
were retrovirally transduced with the pSUPERIOR-retro-puro-
miR-328 (6.15-WT-uORF-miR-328) or with the empty vector
(6.15-WT-uORF-pSUP). Differentiation assays confirmed that
the ability of miR-328 to induce neutrophil maturation is depen-
dent on and mediated by the presence of CEBPA mRNA, as
expression of miR-328 in parental 6.15 cells failed to rescue
differentiation, whereas 91.7% ± 6.4% of 6.15-WT-uORF-miR-
328 cells were postmitotic after 7 days of culture in G-CSF
(Figure 5B). Furthermore, forced miR-328 expression neither
decreased hnRNPE2 protein nor increasedCEBPAmRNA levels
(Figure 5C), suggesting that the restoration of C/EBPa protein
expression in 6.15-WT-uORF-miR-328 cells (Figure 5C) results
from the ability of miR-328 to interfere with hnRNP E2 translation
inhibitory activity. Accordingly, anti-hnRNP E2 RIP assays per-
formed with 6.15-WT-uORF-pSUP and 6.15-WT-uORF-miR-
328 lysates revealed that miR-328 expression and, therefore,
formation of the hnRNP E2:miR-328 complex (Figure 5D) mark-
edly decreased levels of the hnRNP E2-bound CEBPA mRNA
(Figure 5D).
To determine whether miR-328 influences the CML-BC-like
disease process induced by transplantation of BCR/ABL-
expressing cells, SCID mice (n = 13 per group) were intrave-
nously injected with 6.15-WT-uORF-miR-328 or 6.15-WT-
uORF-pSUP cells (5 3 105 GFP+-puromycin-selected cells/
mouse), and engraftment was assessed 1 week later by nested
RT-PCR-mediated BCR/ABL detection in peripheral blood (not
shown). After 3 weeks, three mice/group were sacrificed forFigure 5. In Vitro and In Vivo Interference of miR-328 with hnRNP E2 T
(A) Levels of newly synthesized 35S-C/EBPa protein in RRL translation reactions
(black), CEBPA mRNA and mature miR-328 RNA oligonucleotides (dark gray),
gray) or in the presence of mature miR-328 (red), or miR-330 (white; negative co
SEM and are representative of three different experiments performed in duplica
recombinant MBP-hnRNP E2.
(B) Wright-Giemsa-stained cytospins of G-CSF-treated (0–7 days) 6.15-pSUP, 6
(C) Left: Levels of hnRNP E2, endogenous and HA-tagged C/EBPa, and GRB2 pro
and miR-328-transduced 6.15-WT-uORF cells; right: RT-PCR and qRT-PCR sho
HA-CEBPA cells either uninfected or infected with pSUP or miR-328 constructs.
(D) RIP assays for CEBPA mRNA (top) and miR-328 (bottom) on anti-hnRNP E2
(lanes 2–5) and 6.15-uORF-miR-328 cells (lanes 6–9). IN: input RNA.
(E) Top: H&E-staining of BM shows maturation of BCR/ABL+ cells in mice injected
uORF cells. Age-matched mice (left) served as a control. FACS analysis shows m
ABL+ cells at 3 weeks post-transplant from BM of 3 mice/group. Bottom: Visualvisual and histopathologic examination of hematopoietic organs
and for flow cytometric quantification of GFP+/GR1+ differenti-
ated BM cells. Consistent with the almost complete hnRNP
E2-dependent translational inhibition of C/EBPa expression in
6.15-WT-uORF cells (Chang et al., 2007), hematoxylin/eosin-
stained sections of BM (Figure 5E), spleen, and liver (not shown)
from 6.15-WT-uORF-pSUP-injected mice showed spleno-
megaly and massive infiltration of myeloid blasts with a low
degree of differentiation. A few myeloid cells undergoing termi-
nal neutrophil differentiation were occasionally observed in BM
from 6.15-WT-uORF-pSUP-injected mice (mean fluorescence
intensity [MFI]: 14.98 ± 1.84 GFP+/GR1+ BCR/ABL+ cells). By
contrast, spleens from 6.15-WT-uORF-miR-328-injected mice
appeared normal in weight or slightly hyperplastic, and histo-
pathologic analysis of BM (Figure 5E), spleen, and liver (not
shown) showed marked infiltration by mature neutrophils and
myeloid precursors at postmitotic stages of differentiation (MFI:
63.84 ± 5.40 GFP+/GR1+ BCR/ABL+ cells) when compared to
age-matched controls (Figure 5E), suggesting that miR-328
also negatively regulates survival pathways in CML-BC although
its major effect appears to be on differentiation. In fact, although
no significant difference in survival time was noted, the remain-
ing 6.15-WT-uORF-pSUP-injected mice died of a CML-BC-like
leukemia, whereas 6.15-WT-uORF-miR-328-injected animals
succumbed from an aggressive CML-CP-like myeloproliferative
disorder (not shown). Altogether, these in vitro and in vivo results
indicate that rescue of granulocytic maturation of differentiation-
arrested BCR/ABL+ cells by miR-328 is likely due to its direct
binding to hnRNP E2 that, in turn, prevents translational inhibi-
tion of CEBPA mRNA.
A BCR/ABL-MAPK-hnRNP E2 Pathway Suppresses
miR-328 Transcription through Inhibition of C/EBPa
We recently reported that high levels of BCR/ABL expression/
kinase activity, as observed in CML-BC (Jamieson et al., 2004;
Schultheis et al., 2005), impair C/EBPa expression through the
MAPK(ERK1/2)-dependent regulation of hnRNP E2 expression/
activity (Changetal., 2007). TodeterminewhetherBCR/ABLuses
the same signaling pathway to suppress miR-328 expression
in CML-BC, miR-328 levels were evaluated in G-CSF-cultured
(24–48 hr) parental and newly established 32D-BCR/ABL cells
treated with imatinib (2 mM) or MEK1 inhibitors U0126 (25 mM)
and CI-1040 (10 mM) and after overexpression (MSCV-Flag-E2)ranslation Inhibition of C/EBPa Expression
programmed with CEBPA mRNA (derived from pcDNA3-WT-uORF-C/EBPa)
CEBPA mRNA and recombinant MBP-hnRNP E2 protein either alone (light
ntrol) RNA oligonucleotides. Data are expressed as percentage of the mean ±
te. Inset: Western blot shows levels of both endogenous RRL hnRNP E2 and
.15-miR-328, and 6.15-WT-uORF-miR-328 cells (mean ± SEM).
teins and miR-328 and snRNA U6 in parental 32Dcl3, 6.15-pSUP-transduced,
w levels of CEBPA mRNA in 32Dcl3, 6.15, 6.15-miR-328, and 6.15-WT-uORF-
GAPDH levels were measured for normalization (mean ± SEM).
(lanes 5 and 9) and nonrelated IgG (lanes 3 and 7) IPs from 6.15-uORF-pSUP
with p-SUPERIOR vector- (middle) and miR-328-transduced (right) 6.15-WT-
ean fluorescence intensity (MFI; mean ± SEM) of differentiated GFP+Gr1+BCR/
analysis and weight of spleens from the same groups of mice (mean ± SEM).
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Figure 6. Pathways Regulating miR-328 Expression
miR-328 levels in 32Dcl3 and/or 32D-BCR/ABL cells (A) treated with imatinib or the MAPK inhibitors U0126 and CI-1040 or (B) expressing a Flag-hnRNP E2 (left)
or a shRNA-targeting hnRNP E2 (right).
(C) Top: Representation of the C/EBPa-binding sites within the miR-328 promoter; bottom: Chromatin immunoprecipitation (ChIP) with anti-HA antibody shows
binding of HA-C/EBPa to miR-328 promoter sequences in 32D-HA-C/EBPa cells (left: ChIP blot; middle: densitometric analysis). Anti-Flag immunoprecipitates
served as negative controls. Bars indicate the mean ± SEM from three independent experiments; northern and western blots (right) show levels of miR-328 and
HA-C/EBPa, respectively, in parental and 32D-HA-C/EBPa cells. U6 snRNA and GRB2 protein levels were used as controls.
(D) Model of the molecular network regulating miR-328 expression in CML-BC and miR-328 decoy activity in BCR/ABL+ myeloid cell differentiation by direct
interference with hnRNP E2 translation inhibition of C/EBPa expression.or shRNA-mediated downregulation (pSR-hnRNP E2 shRNA) of
hnRNP E2. Inhibition of BCR/ABL or MEK1 kinases strongly
enhanced miR-328 expression (Figure 6A), suggesting that
BCR/ABL-mediated suppression of miR-328 requires MAP-
K(ERK) activity. Ectopic hnRNP E2 impairedmiR-328 expression
in 32Dcl3 cells, with no noticeable effect in 32D-BCR/ABL
cells (Figure 6B) that already express high levels of hnRNP E2
(Perrotti et al., 2002). By contrast, shRNA-mediated downregula-
tion of hnRNP E2 efficiently rescued miR-328 expression (Fig-
ure 6B). Thus, the BCR/ABL-MAPK-induced hnRNP E2 may
directly regulate miR-328 nuclear export, processing, and/or
stability or indirectly influence miR-328 transcription. Of interest,
modulation of hnRNP E2 levels did not alter miR-223 expression
in 32D-BCR/ABL cells, whereas hnRNP E2 overexpression
inhibited miR-223 in 32Dcl3 cells (Figure S2E), consistent with
the notion that hnRNP E2 reduces C/EBPa expression (Perrotti
et al., 2002), thereby avertingC/EBPa-dependentmiR-223 trans-
activation (Fazi et al., 2005).
Transcription Element Search System-mediated (http://www.
cbil.upenn.edu/cgi-bin/tess) sequence analysis revealed four
putative C/EBPa-binding sites scattered within 1500 bp
upstream of the mouse pre-miR-328 (Figure 6C). Thus, chro-
matin immunoprecipitation (ChIP) assays were performed
using nuclear extracts from GFP-sorted HA-C/EBPa-expressing
32Dcl3 cells (32D-HA-C/EBPa) and four sets of primers, each660 Cell 140, 652–665, March 5, 2010 ª2010 Elsevier Inc.encompassing one of the potential C/EBPa-binding sites. In vivo
physical interaction between HA-C/EBPa and the miR-328 pro-
moter region was detected in ChIP assays performed on anti-HA
but not anti-Flag (negative control) immunoprecipitates with
primer sets #1 and #3 containing the human/mouse-conserved
C/EBPa-binding sites located at nucleotides 1119 to 1112
and 565 to 557, respectively (Figure 6C). Accordingly,
ectopic C/EBPa expression markedly induced miR-328 levels
in myeloid precursors (Figure 6C), altogether suggesting that
a BCR/ABL-MAPK-hnRNP E2 pathway downregulates miR-
328 expression through inhibition of C/EBPa, thus impeding
enhancement of miR-328 transcription (Figure 6D).
miR-328 Impairs CML-BCCD34+ Clonogenic Potential
and Canonically Suppresses PIM1 Expression
Ectopic miR-328 expression reduced colony formation in 32D-
BCR/ABL, Lin SCLtTA-BCR/ABL (n = 5), and CML-BCCD34+
(n = 2) BM cells by 75%, 83%, and 75%, respectively (Figure 7A).
The effect of miR-328 on clonogenicity of BCR/ABL+ cells is
independent from hnRNP E2:miR-328 interaction, as shRNA-
mediated hnRNP E2 downregulation did not affect BCR/ABL-
driven colony formation (Figure 7A). Thus, miRanda, PicTar, and
TargetScan bioinformatics algorithms were utilized to identify
miR-328 targets regulating CML-BC progenitor cell survival.
Among the predicted miR-328 human/mouse mRNA targets,
PIM1 (Figure 7B) kinase is important for survival of BCR/ABL+
cell lines (Nieborowska-Skorska et al., 2002). PIM1 protein was
strongly upregulated in a BCR/ABL kinase-dependent manner
in cell lines and CD34+ CML-BC (n = 2) versus CML-CP and
NBM BM cells (Figure 7C).
Ectopic miR-328 expression in 32D-BCR/ABL, K562, and
CML-BCCD34+ cells decreased PIM1 protein without significantly
affecting its mRNA levels (Figure 7D), suggesting that miR-328
might impair mRNA translation upon interaction with the PIM1
30UTR. To formally demonstrate that miR-328 silences PIM1
expression through its interaction with the miR-328-binding
site, we cloned the wild-type (pMX-Flag-WTPIM1-WT30UTR)
and miR-328-binding site-deleted (pMX-Flag-WTPIM1-D30UTR)
PIM1 30UTR (Figure 7E) into a pMX-Flag-WTPIM1 plasmid
and transduced these constructs into 32D-BCR/ABL-miR-328
or, as a negative control, 32D-BCR/ABL-miR-223 cells. As
expected, ectopic Flag-PIM1 expression was lower in pMX-
Flag-WTPIM1-WT30UTR-transduced 32D-BCR/ABL-miR-328
cells but not in cells transduced with pMX-Flag-WTPIM1-
D30UTRorwithPIM1 cDNAonly (pMX-Flag-WTPIM1) (Figure 7E).
Accordingly, Flag-PIM1 expression derived from pMX-Flag-
WTPIM1-WT30UTR was barely detectable in miR-328- but not
in miR-223-transduced cells, in which its expression was similar
to that of Flag-WTPIM1 and Flag-WTPIM1-D30UTR (Figure 7E),
indicating that decreased ectopic PIM1 levels are not due to
loss of other miRNA-binding sites within the 196 bp-deleted
30UTR. Expression of the seed sequence-mutated mir-328
(miR-328-Mut) impaired the ability of miR-328 to canonically
suppress PIM1 expression (Figure 7F). Thus, miR-328 specifi-
cally silences PIM1 expression through interaction with the
PIM1 30UTR. In agreement with the importance of PIM1 for
survival of BCR/ABL+ cells, expression of a wild-type PIM1
cDNA lacking the 30UTR (WT PIM1) but not of a kinase-deficient
(KD PIM1) PIM1 cDNA into 32D-BCR/ABL-miR-328 cells
(Figure 7G) completely restored IL-3-independent colony forma-
tion (Figure 7G), suggesting that miR-328-dependent inhibition
of BCR/ABL-driven clonogenic potential results from direct
PIM1 downregulation. Note that WT PIM1 alone did not affect
32D-BCR/ABL-pSR-EV clonogenic potential (Figure 7G).
DISCUSSION
Altered miRNA expression has been tightly associated with
cancer development and progression (Friedman et al., 2009;
Garzon et al., 2006). Among the miRNAs differentially expressed
in CML, we focused on miR-328 and provided a series of
evidence highlighting two important concepts. The first repre-
sents a paradigm shift to the notion that miRNAs act primarily
as negative posttranscriptional regulators of gene expression
and proposes for miRNAs a function termed decoy activity.
The second identifies miR-328 as a molecular relay, the loss of
which is important for the differentiation arrest of progressing
CML-BC blasts.
miR-328 Decoy Activity
As miRNAs base pair with mRNA 30UTRs in a sequence-specific
manner (Bartel, 2009), it is conceivable that miRNAs could inter-
fere with the activity of RNA-binding proteins (e.g., hnRNPs),either indirectly by pairing with RBP-binding sites contained in
specific mRNAs (George and Tenenbaum, 2006) or directly
through binding the RBP itself and impeding RBP:mRNA interac-
tion. Herein we demonstrated that miRNAs can act as direct
inhibitors of RBP activity. In fact, miR-328 specifically interacts
in a seed sequence-independent manner and, most likely,
through its C-rich clusters, with the translational inhibitor poly
(rC)-binding protein hnRNP E2. This, in turn, prevents and/or
displaces CEBPA mRNA binding to hnRNP E2 and rescues
CEBPA mRNA translation both in vitro and in vivo. In support
of the notion that miR-328 and, most likely, other miRNAs may
act as ‘‘decoy’’ molecules for RBPs, which upon binding could
control synthesis, processing, export, stability, and/or transla-
tion of specific mRNA subsets, a proteomics-based study in
epithelial A431 cells reported that forced miR-328 expression
not only decreased levels of different genes but also upregulated
a subset of proteins (Wang et al., 2008). Interestingly, 37% of
these upregulated proteins have mRNAs with complex 50UTRs
(e.g., uORF or multiple ATGs) containing C-rich elements repre-
senting potential hnRNP E2-binding sites. Thus, it is reasonable
to speculate that upregulation of some of these proteins might
result from interference with hnRNP E2 activity. Furthermore,
there is evidence that miRNAs, other components of the RISC
complex (Parker and Sheth, 2007) and RBPs (e.g., hnRNP E2)
are present in processing bodies (P bodies) (Fujimura et al.,
2008), dynamic subcellular structures where mRNAs are com-
plexed with RBPs and/or miRNAs for translational suppression
or decay (Parker and Sheth, 2007). In this scenario, miR-328
may compete with CEBPA mRNA for binding to hnRNP E2
that, in turn, releases CEBPA and allows its loading onto poly-
somes for translation. It is also possible that hnRNP E2 not
only prevents C/EBPa-dependent induction of pri-miR-328 tran-
scription but also directly promotes miR-328 decay. Accord-
ingly, an inverse correlation exists between hnRNP E2 and
miR-328 expression in CML-BC, and hnRNP E2 more efficiently
binds tomiR-328 than toCEBPA. However, as hnRNP E2 contin-
uously shuttles between nucleus and cytoplasm as well as in and
out of P bodies (Fujimura et al., 2008; Makeyev and Liebhaber,
2002), knowledge of the subcellular location where initial binding
of hnRNP E2 to miR-328 or CEBPA occurs remains elusive,
although a plausible assumption is the cytoplasm as their asso-
ciation was detected using cytoplasmic extracts.
MicroRNA interaction with sequence-specific RBPs is not
unprecedented; however, none of the reported mechanisms
match the case of hnRNP E2 and miR-328. For example, hnRNP
A1, another RBP upregulated in CML-BC (Perrotti and Neviani,
2007), binds the primary miR-17-92 transcript to allow process-
ing of pre-miR-18a (Guil and Caceres, 2007). Interestingly,
expression of the miR-17-92 cluster is upregulated in CML and
is important for proliferation and reduced susceptibility to
apoptosis of K562 cells (Venturini et al., 2007). However hnRNP
E2:miR-328 interaction does not seem to affect miR-328 biogen-
esis, as no accumulation of primary or precursor miR-328 was
detected in BCR/ABL+ cells (not shown). It was also shown
that miR-369-3 interacts with the AU-rich region (ARE) of TNF-a
mRNA, which recruits the AGO2-FXR1 RBP complex to the ARE
element itself and upregulates or represses translation under
serum-starved or proliferating conditions, respectivelyCell 140, 652–665, March 5, 2010 ª2010 Elsevier Inc. 661
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Figure 7. miR-328 Impairs Survival through Targeting of PIM1 Kinase mRNA
(A) IL-3-independent or -dependent methylcellulose colony formation (mean ± SEM from triplicates of three independent experiments) of vector- (gray bars) and
miR-328-transduced (red bars) 32D-BCR/ABL cells (IL-3-independent), leukemic Lin SCLtTA-BCR/ABL (n = 5) (IL-3-dependent) cells, CML-BCCD34+ (n = 2)
(IL-3 dependent) BM progenitors, and vector- (pSUPER) or hnRNP E2 shRNA (pSUPER-shE2)-infected 32D-BCR/ABL cells (IL-3-independent). Inset: Western
blot shows hnRNP E2 levels upon shRNA knockdown.
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(Vasudevan et al., 2007). However, it is unlikely that hnRNP E2 is
recruited to CEBPA mRNA by miR-328, as no miR-328 target
sites are present in the 50 and 30UTRs of human and mouse
CEBPA mRNA. Because our data indicate that miR-328 binds
hnRNPE2 in a seed sequence-independentmanner and strongly
prevents its interaction with the C-rich intercistronic element of
CEBPA mRNA, it is safe to conclude that hnRNP E2 binding to
miR-328 and CEBPA mRNA are mutually exclusive. Interest-
ingly, as binding to hnRNP E2 is mediated by the C-rich nucleo-
tide clusters present in miR-328, it is possible that miR-328 also
alters the function of other hnRNPs (PCBP1 and hnRNP K) that,
like hnRNP E2, bind C-rich elements within the 50 and 30UTRs
(Ostareck-Lederer and Ostareck, 2004). Indeed, preliminary
data indicate that miR-328 interacts with hnRNP K, albeit with
a lower affinity than the interaction with hnRNP E2 (not shown).
Because hnRNP K expression/activity is also enhanced in
CML-BCCD34+ cells in a BCR/ABL-MAPK-dependent manner
(Notari et al., 2006), and both hnRNP K and hnRNP E2 are essen-
tial for IRES-mediated induction of MYC mRNA translation
(Evans et al., 2003), we can speculate that loss of miR-328 in
CML might favor disease progression by also promoting hnRNP
K/E2-dependent MYC translation activation. Seemingly, we can
also speculate that the mRNA stabilizing and destabilizing
activity of the AU-rich element (ARE) RNA-binding proteins
AUF1 (hnRNP D) and HuR (Lal et al., 2004), respectively, can
be influenced by the putative decoy activity of miRNAs bearing
the ARE element in their nucleotide sequence (e.g., miR-95;
uucaacggguAUUUAuugagca). Indeed, TargetScan-based anal-
ysis revealed that several mature miRNAs contain the AUUUA
element in their sequence. Thus, it is conceivable that these
miRNAs can antagonize the ability of AUF1 and HuR to regulate
expression of mRNAs encoding cytokine receptors (e.g.,
GM-CSF, TNF-a, and interleukins), oncogenes (e.g., c-Myc
and FOS), tumor suppressors (e.g., p53), and cell-cycle regula-
tors (e.g., p21 and cyclin D1) (Hinman and Lou, 2008; Khabar,
2005; Lal et al., 2004). Likewise, the function of the CGG-repeat
binding FMRP RBP, which is the cause of the Fragile X mental
retardation syndrome and normally regulates translation of
mRNAs controlling synaptic function (Brown et al., 2001; Darnell
et al., 2001; Zalfa et al., 2003), might be influenced by the altered
expression of CGG-rich miRNAs (e.g., miR-572 and miR-638).
Thus, it is likely that the decoy activity of miRNAs is not limited
to miR-328 but can be extended to other miRNAs containing(B) miR-328-binding site (red) within the 30UTR of mouse and human PIM1 mRN
(C) PIM1 protein levels in 32Dcl3, untreated or imatinib-treated 32D-BCR/ABL (wi
(NBM), CML-CP, and CML-BC patients (middle); and in the CD34, untreated an
(D) Left: Effect of miR-328 expression on PIM1 protein levels in 32D-BCR/ABL, K5
right: PIM1mRNA expression by qRT-PCR in 32Dcl3, vector-transduced, andmiR
pendent experiments (mean ± SEM).
(E) Left: Levels of ectopic Flag-PIM1 proteins from constructs lacking (pMX-Flag
base pair end-terminal-deleted (pMX-Flag-WTPIM1-D30UTR) PIM1 30UTR in mi
miR-223, miR-328, and snRNA U6. Right: Schematic representation of the Flag-
(F) Effect of seed sequence-mutated (miR-328-Mut) on endogenous PIM1 express
infected 32D-BCR/ABL cells.
(G) Left: Endogenous and ectopic (wild-type [WT PIM-1] and kinase-deficient [K
32D-BCR/ABL cells; right: graph shows rescue of IL-3-independent clonogenic
(black) by ectopic wild-type (red) but not kinase-deficient (yellow) PIM1 constru
clonogenicity (gray). Bars represent the mean ± SEM of colony numbers from thnucleotide sequences resembling the consensus RNA-binding
sites for RBPs that are involved in different normal cell functions
and in neoplastic as well as non-cancer-related diseases.
miR-328: AMolecular Relay in CMLDisease Progression
Even though a few miRNAs are aberrantly regulated in CML
(Agirre et al., 2008; Bueno et al., 2008; Venturini et al., 2007),
evidence of their involvement in disease progression is still lack-
ing. The failure of myeloid CML-BC progenitors to undergo
maturation depends on increased BCR/ABL activity which, in
addition to enhancing survival, proliferation, genomic instability,
and self-renewal (Melo and Barnes, 2007), allows the hnRNP E2
inhibitory effect on C/EBPa that, per se, is sufficient to reinstate
differentiation of Ph(+) blasts (Ferrari-Amorotti et al., 2006; Per-
rotti et al., 2002). We demonstrated that loss of miR-328 occurs
in CML-BCCD34+ but not CML-CPCD34+ myeloid progenitors, and
that forced miR-328 expression at physiological levels rescues
C/EBPa-driven granulocytic maturation and impairs survival of
CML-BC blasts. However, the proapoptotic effect of miR-328
does not seem to depend on its decoy activity and, therefore,
on C/EBPa-induced differentiation and growth arrest (Keeshan
et al., 2003), as shRNA-mediated hnRNP E2 downregulation
does not influence BCR/ABL-driven clonogenic potential.
Rather, we showed that impaired colony formation is the conse-
quence of miR-328 canonical activity that targets PIM1 mRNA,
thus repressing PIM1 expression and survival-promoting activity
(Hoover et al., 2001; Nieborowska-Skorska et al., 2002). Indeed,
forced expression of a wild-type, but not a kinase-deficient,
PIM1 cDNA lacking the 30UTR into miR-328-expressing cells
fully rescued BCR/ABL clonogenicity. However, the main
in vivo effect of miR-328 seems to be on differentiation rather
than survival, as forced miR-328 expression did not delay leuke-
mogenesis but reverted the blast crisis-like phenotype to a dis-
ease that resembles a myeloproliferative-like disorder, although
the absence ofmarked splenomegalymay suggest that a portion
of miR-328+/BCR/ABL+ cells underwent apoptosis. Although
miR-223 was also described as a positive regulator of neutrophil
maturation in APL cells (Fazi et al., 2005), our data in primary
leukemic samples and work in miR-223 knockout animals (John-
nidis et al., 2008) argue against a general role for miR-223 as an
inducer of myeloid differentiation.
Mechanistically, we showed that BCR/ABL uses the same
MAPK(ERK1/2)-hnRNP E2 signaling pathway (see model inA.
ld-type and T315I) and K562 cells (left); in CD34+ BM cells from healthy donors
d imatinib-treated CD34+ BM fractions from a CML-BC patient.
62, and CML-BCCD34+ BM cells. 32Dcl3 cells were used as a negative control;
-328-transduced 32D-BCR/ABL. Representative of triplicates from three inde-
-WTPIM1) and harboring the wild-type (pMX-Flag-WTPIM1-WT30UTR) or 196
R-223- or miR-328-expressing 32D-BCR/ABL. Northern blot shows levels of
PIM1 constructs.
ion in parental 32Dcl3 and empty vector (pCDH)-, miR-328-, andmiR-328-Mut-
D PIM-1]) PIM1 protein levels in 32Dcl3, pSUPER- and pSR-miR-328-infected
activity of miR-328-expressing (white) 32D-BCR/ABL cells to normal levels
ct lacking the 30UTR. Effect of PIM1 forced expression on vector-transduced
ree independent experiments.
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Figure 6D) to suppress C/EBPa (Chang et al., 2007) andmiR-328
expression. Notably, constitutive MAPK activation by BCR/ABL
occurs in CML-BC but not CML-CP (Notari et al., 2006). More-
over, similar to the positive feedback loop described for miR-
223 and C/EBPa (Fazi et al., 2005), we showed that C/EBPa
also interacts with the miR-328 promoter, thus enhancing its
transcription.
In conclusion, the discovery of dual activities for miR-328 that
profoundly affect myeloid cell differentiation and survival not only
add a new layer to the complexity of mechanisms regulating the
phenotype of CML-BC progenitors but, more importantly, high-
light the ability of miRNAs to alter mRNA metabolism by acting
also as molecular decoys for RNA-binding proteins.EXPERIMENTAL PROCEDURES
Additional details on all the methods are available online in the Extended
Experimental Procedures.Clonogenic and Viability Analysis
Methylcellulose clonogenic assays were carried out by plating 103 32Dcl3 and
derivative cell lines, 104 CML-BCCD34+, or 104 Lin SCLtTA-BCR/ABL BM
progenitors in 0.9% MethoCult (Stem Cell Technologies) in the presence or
absence of rIL-3 (100 ng/ml). Colonies (>100 mm) from cell lines and primary
cells were scored 7 and 15 days later, respectively. Human and mouse cell
lines and primary cell source and culture conditions as well as plasmids and
retro/lentiviral vectors are reported in the Extended Experimental Procedures.In Vitro and In Vivo Differentiation Assays
In vitro granulocytic differentiation was induced for 7–10 days with 25 ng/ml
rG-CSF.Morphologic differentiation was assessed byWright/Giemsa staining.
For in vivo differentiation, 10-week-old ICR-SCID mice (n = 13 per group) were
intravenously (i.v.) injected (53 105 cells/mouse) with pSUPERIOR.retro.puro-
or pSUP-miR-328-transduced 6.15-WT-uORF-CEBPA(GFP+) cells.RNA Extraction, Northern Blot, and Real-Time PCR
Total RNA was used in northern blot, RT-PCR, and/or qRT-PCR for the anal-
ysis of miRNA and mRNA expression. U6 snRNA and GAPDH levels were
analyzed for normalization of miRNA and mRNA PCRs, respectively.REMSA, UV Crosslinking, and RNA Immunoprecipitation
Recombinant MBP-hnRNP E2 (Chang et al., 2007) and 32Dcl3 or 32D-BCR/
ABL cytoplasmic extracts were used in REMSA and UV crosslinking as
described (Perrotti et al., 2002). RIP and miR-328 RT-PCR were performed
as described (Keene et al., 2006; Wang et al., 2008).In Vitro Translation Assay
In vitro translation assays using the transcription/translation-coupled rabbit
reticulocyte lysate system (Promega) were performed with pcDNA3-WT-
uORF-C/EBPa in the presence or absence of 1 mg recombinant MBP-hnRNP
E2 (Perrotti et al., 2002) either with or without 10003 mature miR-328 or
miR-330 oligoribonucleotides.Western Blotting, Coimmunoprecipitation, and ChIP Assays
For western blot, 1 3 107 cells were lysed (0C; 30 min) in 50–100 ml RIPA
buffer, clarified, and subjected to SDS-PAGE. For C/EBPa detection, 106 cells
were directly lysed in 20 ml Laemmli buffer and denatured prior to SDS-PAGE
and transfer to nitrocellulose. For coIP, cells were lysed on ice with immuno-
precipitation buffer and 1.0 mg of protein was used in coimmunoprecipitation
assays. Chromatin immunoprecipitation (ChIP) assays were performed using
an EZ-Chip kit (Millipore).664 Cell 140, 652–665, March 5, 2010 ª2010 Elsevier Inc.Statistics
Data were analyzed as follows: (1) two-tailed paired Student’s t test for assays
with identical cell lines, untreated and imatinib-treated SCLtTA-BCR/ABL
cells, RIP assay densitometric and qRT-PCR, and in vitro translation assays;
(2) two-tailed independent Student’s t test for clonogenic assays with unpaired
miRNA-infected Lin BM cells; and (3) the Mann-Whitney rank sums test for
assays with unpaired CML patient samples. A p value of less than 0.05 was
considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
two figures and can be found with this article online at doi:10.1016/j.cell.
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